ArticleEvidence-based medicine2016

In individuals at intermediate risk for cardiovascular disease, treatment with rosuvastatin but not candesartan plus hydrochlorothiazide lowers cardiovascular disease event rates.

No numbers read from the abstract.

Not cited yet